Further, combined treatment using DFMO with celecoxib (a nonsteroidal anti‐inflammatory drug) have synergistic antitumor effects in NB models exhibiting ALK mutation, MYCN amplification, and TP53 mutation with multidrug resistance.158. Here, TP53 is linked to neuroblastoma.